JP2020524994A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524994A5
JP2020524994A5 JP2019568660A JP2019568660A JP2020524994A5 JP 2020524994 A5 JP2020524994 A5 JP 2020524994A5 JP 2019568660 A JP2019568660 A JP 2019568660A JP 2019568660 A JP2019568660 A JP 2019568660A JP 2020524994 A5 JP2020524994 A5 JP 2020524994A5
Authority
JP
Japan
Prior art keywords
cell
zfns
called
gene
zfn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568660A
Other languages
English (en)
Japanese (ja)
Other versions
JP7419073B2 (ja
JP2020524994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037844 external-priority patent/WO2018232296A1/en
Publication of JP2020524994A publication Critical patent/JP2020524994A/ja
Publication of JP2020524994A5 publication Critical patent/JP2020524994A5/ja
Priority to JP2022137773A priority Critical patent/JP7482176B2/ja
Application granted granted Critical
Publication of JP7419073B2 publication Critical patent/JP7419073B2/ja
Priority to JP2024017157A priority patent/JP2024036610A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568660A 2017-06-16 2018-06-15 Ｔ細胞および／またはｈｌａ受容体の標的化破壊 Active JP7419073B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022137773A JP7482176B2 (ja) 2017-06-16 2022-08-31 Ｔ細胞および／またはｈｌａ受容体の標的化破壊
JP2024017157A JP2024036610A (ja) 2017-06-16 2024-02-07 Ｔ細胞および／またはｈｌａ受容体の標的化破壊

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762521132P 2017-06-16 2017-06-16
US62/521,132 2017-06-16
US201762542052P 2017-08-07 2017-08-07
US62/542,052 2017-08-07
US201762573956P 2017-10-18 2017-10-18
US62/573,956 2017-10-18
PCT/US2018/037844 WO2018232296A1 (en) 2017-06-16 2018-06-15 Targeted disruption of t cell and/or hla receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022137773A Division JP7482176B2 (ja) 2017-06-16 2022-08-31 Ｔ細胞および／またはｈｌａ受容体の標的化破壊

Publications (3)

Publication Number Publication Date
JP2020524994A JP2020524994A (ja) 2020-08-27
JP2020524994A5 true JP2020524994A5 (https=) 2021-06-17
JP7419073B2 JP7419073B2 (ja) 2024-01-22

Family

ID=64656803

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019568660A Active JP7419073B2 (ja) 2017-06-16 2018-06-15 Ｔ細胞および／またはｈｌａ受容体の標的化破壊
JP2022137773A Active JP7482176B2 (ja) 2017-06-16 2022-08-31 Ｔ細胞および／またはｈｌａ受容体の標的化破壊
JP2024017157A Pending JP2024036610A (ja) 2017-06-16 2024-02-07 Ｔ細胞および／またはｈｌａ受容体の標的化破壊

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022137773A Active JP7482176B2 (ja) 2017-06-16 2022-08-31 Ｔ細胞および／またはｈｌａ受容体の標的化破壊
JP2024017157A Pending JP2024036610A (ja) 2017-06-16 2024-02-07 Ｔ細胞および／またはｈｌａ受容体の標的化破壊

Country Status (11)

Country Link
US (1) US20230295563A1 (https=)
EP (1) EP3638783A4 (https=)
JP (3) JP7419073B2 (https=)
KR (1) KR102708624B1 (https=)
CN (1) CN110997913B (https=)
AU (1) AU2018283310B2 (https=)
BR (1) BR112019026622A2 (https=)
CA (1) CA3066641A1 (https=)
IL (1) IL271298A (https=)
SG (1) SG11201911729SA (https=)
WO (1) WO2018232296A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015355A2 (pt) * 2017-01-26 2020-05-19 Sangamo Therapeutics Inc modificação genética de células b
KR20210060533A (ko) * 2018-09-18 2021-05-26 상가모 테라퓨틱스, 인코포레이티드 프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제
CN116323921A (zh) 2020-10-28 2023-06-23 桑格摩生物治疗股份有限公司 从人多能干细胞生成cd4+效应t细胞和调节性t细胞
CN113846070B (zh) * 2021-10-18 2023-05-16 翌圣生物科技(上海)股份有限公司 高活性的mTET2酶突变体、其编码DNA及其应用
CN118325904B (zh) * 2024-06-17 2024-10-01 天海元祺生物科技(天津)有限公司 高度靶向人类HLA-A基因的sgRNA、其组合物及应用
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
WO2026083328A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Base editing nucleotide sequences using homology directed repair

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004235395A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
AU2009239333A1 (en) * 2008-04-21 2009-10-29 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
KR101551555B1 (ko) * 2011-03-17 2015-09-08 밀테니 비오텍 게앰베하 Tcr 알파/베타가 고갈된 세포 제제
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
CA3131284C (en) * 2013-08-28 2023-09-19 David Paschon Compositions for linking dna-binding domains and cleavage domains
JP6681837B2 (ja) * 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
US20170037431A1 (en) * 2014-05-01 2017-02-09 University Of Washington In vivo Gene Engineering with Adenoviral Vectors
AU2016291778B2 (en) * 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3389677B1 (en) * 2015-12-18 2024-06-26 Sangamo Therapeutics, Inc. Targeted disruption of the t cell receptor
BR112018012235A2 (pt) * 2015-12-18 2018-12-04 Sangamo Therapeutics Inc rompimento alvejado do receptor de células de mhc
AU2018313167A1 (en) * 2017-08-08 2020-02-27 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
CA3089587A1 (en) * 2018-02-08 2019-08-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases

Similar Documents

Publication Publication Date Title
JP2020524994A5 (https=)
Han et al. Generation of hypoimmunogenic human pluripotent stem cells
JP7396783B2 (ja) 移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物
JP2019517803A5 (https=)
Youngblood et al. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells
JP2021502085A5 (https=)
JP2018532428A5 (https=)
MY185961A (en) Methods and compositions for gene editing in hematopoietic stem cells
JP2017504354A5 (https=)
Linscheid et al. Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy
JP2016513460A5 (https=)
NZ743429A (en) Targeted disruption of the mhc cell receptor
JP2016521975A5 (https=)
JP2025504392A5 (https=)
JP2024177252A (ja) カルボジイミドで処理された寛容化ワクチンによる移植寛容誘導
Fiorini et al. Dysfunctional telomeres and hematological disorders
Kim et al. Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout
FI3169778T3 (fi) Ituradan soluja ablatoiva nanos-geeninpoisto
Sin et al. Transplantation of gene-edited hepatocyte-like cells modestly improves survival of arginase-1-deficient mice
JP7416745B2 (ja) 改変細胞、調製方法、及び構築物
Hoff et al. Recipient HLA-C haplotypes and microRNA 148a/b binding sites have no impact on allogeneic hematopoietic cell transplantation outcomes
Beck‐Engeser et al. APOBEC3 enzymes restrict marginal zone B cells
JP2019531754A5 (https=)
JP2025072470A (ja) ホーミングエンドヌクレアーゼバリアント
Aigner et al. Genetically tailored pig models for translational biomedical research